Stock IGX INTELGENX TECHNOLOGIES CORP.
Add to a list
To use this feature you must be a member
Log inSign up

News IntelGenx Technologies Corp. Toronto S.E.

Equities

IGX

US45822R1014

End-of-day quote Toronto S.E.
Other stock markets
 06:00:00 2021-10-17 pm EDT 		5-day change 1st Jan Change
0.78 CAD +9.86% Intraday chart for IntelGenx Technologies Corp. +50.00% +173.68%
Apr. 08 Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial CI
Apr. 05 IntelGenx Updates Status of Buprenorphine Buccal Film ANDA MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial
GL
Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial
CI
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
AQ
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
MT
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
GL
IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA
CI
IntelGenx Technologies Narrows Q4 Loss, Revenue Rises
MT
Transcript : IntelGenx Technologies Corp., Q4 2023 Earnings Call, Mar 21, 2024
IntelGenx Technologies Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results
GL
IntelGenx Technologies : 25 10.42pm MOCK-UP with special characters / * $ % + ` ' ' `
PU
IntelGenx Technologies : 26 10.45pm MOCK-UP with special characters / * $ % + ` ' ' `
PU
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow
GL
IntelGenx Subsidiary Signs Third Amended, Restated Loan Agreement With atai Life Sciences
MT
IntelGenx Brief: Entering Into a Third Amended and Restated Loan Agreement With atai Life Sciences
MT
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences
GL
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences
AQ
IntelGenx Technologies Corp. announced that it expects to receive $2 million in funding
CI
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering
GL
IntelGenx Brief: Launching Regulation A Offering of Up to 2 Million shares In Series A Convertible Cumulative Preferred Stock, Par Value $0.00001 Per Share, at an Offering Price of $10.00 Each, For a Max Offering amount of $20 Million
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IGXT Stock
  4. IGX Stock
  5. News IntelGenx Technologies Corp.